The images showed that nearly all the antibodies bind to a single domain of the receptor, providing a viable target for novel therapeutics.

In this GEN webinar, Guilherme Yamamoto, MD, PhD, and Sevana Yaghoubian will present a novel whole-exome assay for detecting high-confidence variants across multiple applications.

SHERLOCK, a rapid CRISPR-based diagnostic, detects Candida auris and antifungal resistance mutations in patient samples in under an hour.

Benefits seen from embracing platform technologies, combined with the role such systems played during the pandemic, are key dynamics.

Avenue Biosciences technology collects data sets on how specific signal peptides impact specific protein targets.

A profound transformation is taking place in therapeutic discovery, development, and delivery.2026 will be a pivotal year for biopharma. From digital transformation to an AI revolution to more ...

Autonomy, by contrast, is about decision‑making and adaptation. The leap from automation to autonomy is not just more actuators; it is a system that can perceive its environment, reason about options, ...

How AI, robotics, and modular design are transforming single-cell and spatial biology into scalable, precision-driven engines of discovery.

Illumina unveiled the Billion Cell Atlas, a large‑scale genetic perturbation dataset built with pharma partners to advance AI‑powered drug discovery, target validation, and disease biology.

Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

Nick Edwards, PhD, CEO of Potato, has a “burning desire” to speed up scientific discovery. In an interview with GEN, he explained how Potato’s AI “scientist,” named Tater, recently replicated a main ...

The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...